Medtronic Expands Cardiovascular Solutions with CathWorks Acquisition

Medtronic's Strategic Acquisition of CathWorks: A Step Forward in Cardiovascular Care

In a significant move to enhance its cardiovascular solutions, Medtronic plc (NYSE: MDT) has completed the acquisition of CathWorks, a medical device company renowned for its innovative technologies aimed at revolutionizing coronary artery disease (CAD) diagnosis and treatment. This acquisition, valued at approximately $585 million, represents a strategic expansion of Medtronic's leadership in healthcare, particularly in interventional cardiology.

The roots of this partnership can be traced back to a successful 2022 co-promotion agreement, which allowed the CathWorks FFRangio® System to become commercially available across the U.S., Europe, and Japan. The FFRangio System stands out as a pioneering device that utilizes artificial intelligence (AI) combined with advanced computational science to conduct comprehensive physiological assessments of the coronary tree directly from routine, non-invasive, drug-free coronary angiograms, setting it apart from traditional wire-based techniques.

Ramin Mousavi, the president and CEO of CathWorks, emphasized the significance of this acquisition, stating, "With the acquisition of CathWorks, we are boldly redefining the future of cardiovascular care." This sentiment reflects the shared vision and commitment between Medtronic and CathWorks to enhance patient outcomes and innovate procedures in the cath lab.

Innovative Technology with FFRangio

The CathWorks FFRangio System is designed to provide FFR values along the entire coronary tree while eliminating the need for invasive pressure wires or pharmacologic hyperemia. This breakthrough allows for quicker and more reliable intraprocedural data, empowering physicians with valuable insights that support patient-centered treatment decisions. The approach marks a significant evolution in how CAD is diagnosed, potentially leading to improved patient outcomes and more efficient resource utilization during procedures.

Recent highlights from the ALL-RISE randomized control trial presented at the 2026 American College of Cardiology conference reaffirm the efficacy of the FFRangio System. The trial included over 1,900 patients across multiple global sites and results demonstrated that the FFRangio approach is non-inferior to traditional methods in terms of major adverse cardiac events (MACE) while boasting advantages such as reduced procedure times and improved resource use.

Jason Weidman, Senior Vice President and President of Medtronic’s Coronary Renal Denervation business, recognized the acquisition's potential to enhance Medtronic's portfolio in interventional cardiology. He stated, "The acquisition of CathWorks significantly enhances our interventional cardiology portfolio with an innovative system that empowers physicians with data-driven insights for CAD diagnosis and treatment."

A Commitment to Growth

This acquisition is also a clear indication of Medtronic's commitment to strategically enhancing its business through impactful mergers and acquisitions. The company aims to maintain its leadership in the healthcare sector by exploring high-growth opportunities that align with its core business objectives.

Skip Kiil, Executive Vice President of Medtronic's Cardiovascular portfolio, highlighted the importance of the acquisition, saying, "This positions Medtronic at the forefront of digital transformation in cardiovascular care, allowing us to deliver next-generation solutions for physicians and their patients."

Financially, the acquisition is expected to be immaterial to Medtronic’s fiscal year 2027 GAAP and adjusted earnings per share, offering potential for growth and value enhancement in the future.

Conclusion

Medtronic has once again demonstrated its commitment to transforming healthcare through strategic innovation. By integrating CathWorks and its state-of-the-art FFRangio technology, Medtronic is poised to make a notable impact on how cardiovascular disease is managed, improving patient outcomes globally. This acquisition not only strengthens Medtronic’s portfolio but also represents a promising future for advancements in cardiovascular care. For more insights about the acquisition and the capabilities of the FFRangio System, visit CathWorks and stay informed about the evolving landscape of healthcare technology.